HALOHealthcare · BiotechnologyThe 9 Wall Street analysts covering Halozyme Therapeutics, Inc. hold a median 12-month price target of $105 — -2.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 12 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Halozyme Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (45): The company has been issuing shares or taking on financing, diluting existing holders.
Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HALO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −2.1% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $115 |
| 8 Aug 2026 | Leerink Partners | Upgrade | Outperform | — |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 7 Aug 2026 | Citizens | Maintains | Market Outperform | $92 → $93 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $95 → $115 |
| 7 Aug 2026 | Leerink Partners | Upgrade | Outperform | $83 → $110 |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 7 Aug 2026 | TD Cowen | Maintains | Buy | $96 → $105 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $75 → $95 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $95 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 12 May 2026 | Morgan Stanley | Maintains | Overweight | $96 → $93 |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Feb 2026 | Benchmark | Maintains | Buy | — |
| 19 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HALO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Halozyme Therapeutics, Inc. returned +38.3% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 24% of US stocks
Cheaper than 18% of US stocks
Cheaper than 2% of US stocks
Cheaper than 26% of US stocks
Higher than 85% of US stocks
Higher than 71% of US stocks
Higher than 93% of US stocks
Higher than 98% of US stocks
Higher than 86% of US stocks
Higher than 98% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Halozyme Therapeutics, Inc. has a market value of $12.2B and an enterprise value of $14.1B.
Revenue in the twelve months to 30 June 2026: $1.7B. The latest quarter grew 47.7% year on year.
Net income over the same four quarters: $413.6M, a 24.9% net margin.
Diluted earnings per share, trailing twelve months: $3.35.
Free cash flow in the twelve months to 30 June 2026: $518.5M.
Trailing P/E: 31.4×; forward P/E: 10.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Halozyme Therapeutics, Inc. employs 423 people — $3.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Halozyme Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Halozyme Therapeutics, Inc. (HALO) shares have risen 769% since March 2014, driven by record revenue growth, according to FXEmpire. The increase has been supported by institutional investors.
Why it matters — The substantial share price increase tied to record revenue growth indicates strong company performance that HALO watchers would want to track.
Halozyme Therapeutics presented at the Wells Fargo 21st Annual Healthcare Conference, with the presentation transcribed by Seeking Alpha. The excerpt provides the transcript of the company's conference presentation.
Why it matters — A HALO watcher would care because investor conferences offer insight into the company's strategy and business update as communicated directly to the investment community.
Zacks Investment Research highlighted four GARP (growth at a reasonable price) stocks that combine discounted PEG ratios with strong growth prospects for 2026, positioning them as value opportunities for investors.
Why it matters — HALO watchers would care because Halozyme may be among the highlighted GARP stocks, suggesting its growth prospects and valuation are being favorably viewed by analysts.
Halozyme Therapeutics announced that its CEO Dr. Helen Torley and CFO Darren Snellgrove are scheduled to participate in and host investor meetings at upcoming investor conferences. The announcement was made on September 2, 2026, from San Diego.
Why it matters — A HALO watcher would care because the company's leadership will be engaging directly with the investment community at these conferences, providing opportunities to present the company's story and plans.
A Seeking Alpha analysis notes that Halozyme is evolving into a diversified, high-margin royalty platform less dependent on single assets like DARZALEX SC. The article points to 48% year-over-year revenue growth in 2Q26, 50% royalty revenue growth, 68% EBITDA margins, raised full-year guidance, and a broadening royalty pipeline with launches expected from 2029 onward.
Why it matters — HALO watchers would care because the article argues the market may be underpricing Halozyme's second growth wave, driven by broadening royalty streams and a more diversified revenue base.
The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. have a median 12-month price target of $105, with estimates ranging from $70 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Halozyme Therapeutics, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Halozyme Therapeutics, Inc. 97 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Halozyme Therapeutics, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies -2.1% from the last close, and Ticker Nerd's factor model ranks Halozyme Therapeutics, Inc. 97 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Halozyme Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HALO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $115 over the next 12 months.
Halozyme Therapeutics, Inc. returned +38.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines.
The most recent item we track (FXEmpire, 11 Sept 2026): "Record Revenue Growth Boosts Halozyme Shares". Halozyme Therapeutics, Inc. (HALO) shares have risen 769% since March 2014, driven by record revenue growth, according to FXEmpire. The increase has been supported by institutional investors.
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. · 423 employees · United States · https://halozyme.com
